Research Resource

Creative Biogene is committed to providing high quality products and services to help scientists around the world find solutions in biological research and drug discovery.

Research Areas

Development, Principles, and Methodological Advances of Yeast Two-Hybrid Technology

Yeast two-hybrid (Y2H) technology is a cornerstone method for probing protein–protein interactions directly within living cells. From its classical nuclear format to membrane-based, cytosolic, split-protein, and sequencing-enabled variants, Y2H has continuously evolved to address increasingly complex biological questions. These methodological advances enable the analysis of diverse protein classes and support scalable interaction discovery, from focused validation to systems-level interactome mapping. Today, Y2H remains a versatile and powerful platform for elucidating cellular mechanisms, signaling networks, and disease-associated protein interactions.

Antibody Fusion Proteins

Antibody fusion proteins (AFPs) are modular engineered biologics that combine the targeting specificity of antibodies with the biological activity of cytokines, enzymes, ligands, or toxins. Through genetic fusion into a single recombinant molecule, AFPs enable precise payload delivery to defined cells or tissues while enhancing stability, pharmacokinetics, and overall therapeutic performance.

An In-Depth Overview of Aptamers

nucleic acid aptamers have become an important class of synthetic ligands with broad potential across biomedical research and therapeutic development. Derived entirely through in vitro selection, these single-stranded oligonucleotides can fold into defined three-dimensional structures that enable high-affinity and high-specificity binding to a wide range of molecular targets. Continuous refinements in SELEX methodology, coupled with advances in chemical modification and screening technologies, have transformed aptamer research from a conceptual framework into practical biomedical applications.

Must-read for industrial clients: Stable, high-yield, high-quality industrial cell line construction methods

With the advent of gene editing and related technologies, cell line development has entered a "designable" era. Precise gene integration, metabolic pathway regulation, and glycosylation optimization now enable modern cell lines to achieve higher productivity, improved stability, and consistent product quality. These advances not only enhance the efficiency of antibody and complex protein development but also provide solutions to reduce risk, shorten development cycles, and strengthen market competitiveness.

How Can Genes Be Switched On or Off on Demand?

Gene expression regulation is a central theme in modern molecular biology, critical for research and biopharmaceutical development. From basic transcriptional control to advanced inducible systems, researchers can now precisely switch genes on or off, modulating expression across time, space, and dosage. Integration of gene editing, omics technologies, and RNA-based regulation enables dynamic control in physiologically relevant models.

RNA Editing: From Laboratory to Clinical Mainstay

RNA editing, as a precise and reversible gene modification technology that does not introduce DNA double-strand breaks, is emerging as an important branch of RNA-based therapeutics. Unlike conventional strategies such as mRNA vaccines, siRNA, or antisense oligonucleotides that primarily alter the expression level of gene products, RNA editing directly corrects single nucleotides on RNA molecules, enabling precise restoration or modification of protein function at the transcript level. With the rapid development of novel editing enzymes, delivery systems, and target design strategies, RNA editing is transitioning from basic research to clinical exploration, showing unique potential in treating rare genetic disorders, neurodegenerative diseases, and certain metabolic conditions.

Rebuilding the Foundations: A Modern Review of Biopharmaceutical Cell Line Development and Quality Control

Cell line development is central to biopharmaceutical production, especially as biologics grow more complex. Modern approaches combine digital monoclonality verification, genetic stability monitoring, and advanced expression system engineering to ensure yield, consistency, and regulatory compliance. These innovations enable efficient, scalable, and high-quality manufacturing of next-generation therapeutics.

CRISPR-GPT: AI-Driven Gene Editing Experimental Design and Analysis System

Discover CRISPR-GPT, an AI-driven gene editing system integrating large language models with CRISPR expertise to automate experimental design, gRNA selection, delivery strategies, and data analysis. This breakthrough lowers barriers for both beginners and experts, accelerates biomedical research, and ensures ethical safeguards in gene editing.

Research Progress on Universal Cell Therapy

In order to allow more patients to benefit from immune cell therapy, researchers are now developing safe and effective allogeneic transplant immune cells and preparing universal CAR-immune cells. The successful development of such products will greatly reduce production costs, shorten production time, and better ensure product efficacy, so that more patients can benefit.

Lentiviral Vectors for CAR-T Cell Therapy

As the core link of CAR-T cell therapy, lentiviral packaging technology plays a vital role in the field of tumor immunotherapy. In-depth research on the biological basis and production process of lentiviral packaging and overcoming the current challenges are of far-reaching significance for promoting the development of CAR-T cell therapy technology and even the progress of the entire field of tumor immunotherapy.

* For research use only. Not intended for any clinical use.

Quick Inquiry